A potent, reversible 20S proteasome inhibitor
Related Products
Labeled Version(s)
22367Bortezomib-d15
Metabolite(s)
36499Bortezomib Impurity A
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Bortezomib

Item No. 10008822

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid
CAS Number
179324-69-7
Synonyms
  • LDP-341
  • MG-341
  • MLN341
  • NSC 681239
  • PS-341
Molecular Formula
C19H25BN4O4
Formula Weight
384.2
Purity
≥95%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 20 mg/mlDMSO: 20 mg/mlDMSO:PBS (pH 7.2)(1:5): 0.1 mg/ml
λmax
269 nm
SMILES
O=C(N[C@@H](CC1=CC=CC=C1)C(N[C@H](B(O)O)CC(C)C)=O)C2=CN=CC=N2
InChi Code
InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
InChi Key
GXJABQQUPOEUTA-RDJZCZTQSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $39

    Add

    5 mg

    $97

    Add

    10 mg

    $154

    Add

    25 mg

    $290

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Bortezomib is a dipeptide boronic acid derivative that reversibly inhibits the 20S proteasome (Ki = 0.6 nM).1 It binds the β5-subunit of the 20S proteasome and selectively inhibits chymotryptic activity.2,3,4 In part by blocking the degradation of tumor-suppressing and proapoptotic proteins, bortezomib drives cell cycle arrest and apoptosis in cancer cell lines and has applications in multiple myeloma and certain lymphomas, as well as other types of cancer.1,5 Proteasome inhibitors, including bortezomib, have potential in combination therapy with chemotherapy and radiation therapy against cancer.6,7,8,9

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Ludwig, H., Khayat, D., Giaccone, G., et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104, 1794-1807 (2005).

    2. Lightcap, E.S., McCormack, T.A., Pien, C.S., et al. Proteasome inhibition measurements: Clinical application. Clin. Chem. 46(5), 673-683 (2000).

    3. Adams, J. Development of the proteasome inhibitor PS-341. The Oncologist 7, 9-16 (2002).

    4. Dou, Q.P., and Zonder, J.A. Overview of proteasome inhibitor-based anti-cancer therapies: Perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr. Cancer Drug Targets 14(6), 517-536 (2014).

    5. Richardson, P.G., Hideshima, T., and Anderson, K.C. Bortezomib (PS-341): A novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10(5), 361-369 (2003).

    6. Mandl-Weber, S., Meinel, F.G., Jankowsky, R., et al. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br. J. Haematol. 149, 518-528 (2010).

    7. Minami, J., Suzuki, R., Mazitschek, R., et al. Histone deacetylase 3 (HDAC3) as a novel therapeutic target in multiple myeloma. Leukemia 28(3), 680-689 (2014).

    8. Mato, A.R., Feldman, T., and Goy, A. Proteasome inhibition and combination therapy for non-Hodgkin’s lymphoma: From bench to bedside. Oncologist 17(5), 694-707 (2012).

    9. Al-Eisawi, Z., Beale, P., Chan, C., et al. Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models. J. Ovarian Res. 6(1), 78 (2013).